HK Stock Market Move | ALEBUND-B (09637) rose over 6%, included in the Hong Kong Stock Connect and the Hang Seng Composite Index. Sales of Moxinlu increased by approximately 105% year-on-year, realizing commercialization.

ALEBUND-B (09637) rose more than 6%. As of the time of publication, it increased by 6.02%, trading at HK$28.52, with a transaction volume of HK$6.4522 million, a volume ratio of 2.26, and a fluctuation of 7.06%. The stock officially joined the Stock Connect and the Hang Seng Composite Index constituents starting September 7 (Monday), with active trading on its first day of inclusion. According to a voluntary announcement by Livzon Pharmaceutical, the company's H-shares have been included in the list of eligible securities for Stock Connect, effective from September 7, 2026. This inclusion is based on the H-shares' admission to the Hang Seng Composite Index, with the quarterly review results announced by Hang Seng Indexes Company on August 21, and the relevant changes implemented after market close on September 4, effective from September 7. An announcement from the Shenzhen Stock Exchange on September 7 also confirmed that 09637 has been added to the Stock Connect eligible securities list. The board believes that this move reflects the capital market's recognition of the company's value and long-term development prospects, helping to broaden the investor base and enhance H-share trading liquidity. As the first pure nephrology innovative drug company listed on the Hong Kong Stock Exchange, Livzon Pharmaceutical's inclusion allows for southern-bound funds to be within investable range, potentially improving liquidity and valuation anchors. Livzon Pharmaceutical disclosed its first interim results post-listing on August 26, reporting revenue of RMB 104.2 million for the first half of 2026, a year-on-year increase of 761.2%, primarily from sales of Mebendazole and AP306 licensing income. The loss for the period was RMB 162.6 million, narrowing by 22.5% year-on-year. Among its commercialized products, Mebendazole achieved sales revenue of RMB 24.8 million, a year-on-year increase of about 105%, covering over 300 hospitals, with the gross profit margin rising from 43.4% in the first half of 2025 to 47.3%. Huatais research report noted that the company had previously reached an exclusive commercialization cooperation with Roche for Mebendazole, which is currently the only product the company has that is commercially available. It is expected that Mebendazole could achieve peak sales of approximately RMB 1 billion in China by 2034. In addition, the new drug application for the core product AP301 was accepted by the National Medical Products Administration in August, and the global Phase III RESPOND-2 trial has also completed enrollment, with the pipeline continuing to deliver results.